Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study examined FAERS data and found an increasing trend in alopecia areata cases, with monoclonal antibodies most frequently linked to the condition.

This review examines the FDA's 510(k) approval process for low-level laser therapy devices used in treating androgenetic alopecia and reports no new clinical findings.

Isotretinoin may cause hair loss, especially in women and young adults.

The FDA approved a new Pfizer drug for hair loss in teens.

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

This pharmacovigilance study found strong disproportionality signals suggesting an association between finasteride and Peyronie's disease-related clinical features, but the evidence does not confirm a causal link.

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

This study analyzed data from the FDA Adverse Event Reporting System and found that finasteride had the highest reporting frequency and signal strength for drug-induced erectile dysfunction among 734 drugs, with compound preparations posing higher risks than single ingredients.

In this study, 18F-FDG PET/CT revealed increased FDG uptake in the scalp of a woman after platelet-rich plasma therapy, indicating potential inflammatory changes.

This review discusses considerations for choosing antihypertensive agents in children, including factors like side effects and FDA approval status, and reports no new clinical results.

This study found that psychiatric adverse drug reactions were more frequently reported with finasteride than with dutasteride, but it remains unclear if there is a causal relationship.

This study detected insomnia risk signals associated with various medications, primarily nervous system drugs, using the FDA's Adverse Event Reporting System data from 2004 to 2024.

This study found that the type of reporter significantly influences the detection of cancer therapy-induced alopecia signals, highlighting differences in signal amplification between patients and healthcare professionals.

This study analyzed data from the FDA Adverse Event Reporting System to evaluate cancer therapy–induced alopecia, finding that reporter type significantly affects signal detection, with docetaxel showing the highest disproportionate association overall, and vismodegib ranking highest among healthcare professional reports.

In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This study analyzed reports from the FDA Adverse Event Reporting System and observed an upward trend in suicidality-related safety signals among young male finasteride users since 2019, peaking in 2022, highlighting emerging psychiatric safety concerns and the need for vigilant monitoring of this population.

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.

This report observed that discontinuation of cyclosporine led to complete hair regrowth in a child with alopecia, suggesting a potential link between cyclosporine and hair loss.

This study found that finasteride use is associated with both known and new adverse events, which vary by gender and age, as well as some events not previously listed in the drug insert.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

This article discusses the FDA approval of bremelanotide for premenopausal women with hypoactive sexual desire disorder and reports no clinical results.

A new acne cream effectively reduced acne in trials and awaits FDA approval.

The FDA approved using Cialis with Proscar for better treatment options.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

In this study, topical minoxidil 7% with dutasteride 0.5 mg showed higher efficacy but more adverse effects compared to minoxidil 7% with finasteride 1 mg for treating androgenetic alopecia.

This review examines the use of apremilast for non-FDA-approved dermatological conditions, noting varied efficacy but a favorable safety profile compared to conventional treatments.